Menu Search
Equities

Medicenna Therapeutics Corp

MDNA:TOR

Medicenna Therapeutics Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)1.57
  • Today's Change0.08 / 5.37%
  • Shares traded34.61k
  • 1 Year change+265.12%
  • Beta1.0906
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in CAD

The 4 analysts offering 12 month price targets for Medicenna Therapeutics Corp have a median target of 4.38, with a high estimate of 8.38 and a low estimate of 3.44. The median estimate represents a 193.96% increase from the last price of 1.49.
High462.4%8.38
Med194.0%4.38
Low130.9%3.44

Earnings history & estimates in CAD

On Nov 13, 2024, Medicenna Therapeutics Corp reported 2nd quarter 2025 losses of -0.05 per share. This result was in line with the consensus of the 3 analysts following the company and was the same as last year's 2nd quarter results.
The next earnings announcement is expected on Feb 12, 2025.
Average growth rate-37.68%
Medicenna Therapeutics Corp reported annual 2024 losses of -0.37 per share on Jun 27, 2024.
Average growth rate-30.99%
More ▼

Revenue history & estimates in CAD

Medicenna Therapeutics Corp. did not report revenues for the 2nd quarter 2025. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Medicenna Therapeutics Corp. did not report revenues for the full year 2024. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.